Claudine M Samanic1, Jamie K Teer2, Zachary J Thompson2, Jordan H Creed1, Brooke L Fridley2, L Burt Nabors3, Sion L Williams4, Kathleen M Egan1. 1. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, United States. 2. Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, United States. 3. Division of NeuroOncology, Department of Neurology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower Suite 1020 Birmingham, Birmingham, AL, United States. 4. UM-CFAR/Sylvester CCC Argentina Consortium for Research and Training in Virally Induced AIDS-Malignancies University of Miami Miller School of Medicine, Miami, FL, United States; Neurology Basic Science Division, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, United States.
Abstract
BACKGROUND: Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. METHODS: We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). RESULTS: In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23-0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47-2.43). In the UKB, the variant m.3010G > A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01-1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78-1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T > C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53-0.99), but not GBM (OR = 0.86; 95%CI: 0.66-1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06-2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52-1.63). None of these associations were significant after adjustment for multiple testing. CONCLUSION: The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.
BACKGROUND: Malignant gliomas are the most common primary adult brain tumors, with a poor prognosis and ill-defined etiology. Mitochondrial DNA (mtDNA) sequence variation has been linked with certain cancers; however, research on glioma is lacking. METHODS: We examined the association of common (minor allele frequency ≥ 5%) germline mtDNA variants and haplogroups with glioma risk in 1,566 glioma cases and 1,017 controls from a US case-control study, and 425 glioma cases and 1,534 matched controls from the UK Biobank cohort (UKB). DNA samples were genotyped using the UK Biobank array that included a set of common and rare mtDNA variants. Risk associations were examined separately for glioblastoma (GBM) and lower grade tumors (non-GBM). RESULTS: In the US study, haplogroup W was inversely associated with glioma when compared with haplogroup H (OR = 0.43, 95%CI: 0.23-0.79); this association was not demonstrated in the UKB (OR = 1.07, 95%CI: 0.47-2.43). In the UKB, the variant m.3010G > A was significantly associated with GBM (OR = 1.32; 95%CI: 1.01-1.73; p = 0.04), but not non-GBM (1.23; 95%CI: 0.78-1.95; p = 0.38); no similar association was observed in the US study. In the US study, the variant m.14798 T > C, was significantly associated with non-GBM (OR = 0.72; 95%CI: 0.53-0.99), but not GBM (OR = 0.86; 95%CI: 0.66-1.11), whereas in the UKB, a positive association was observed between this variant and GBM (OR = 1.46; 95%CI: 1.06-2.02) but not non-GBM (OR = 0.92; 95%CI: 0.52-1.63). None of these associations were significant after adjustment for multiple testing. CONCLUSION: The association of inherited mtDNA variation, including rare and singleton variants, with glioma risk merits further study.
Authors: Simon N Stacey; Patrick Sulem; Aslaug Jonasdottir; Gisli Masson; Julius Gudmundsson; Daniel F Gudbjartsson; Olafur T Magnusson; Sigurjon A Gudjonsson; Bardur Sigurgeirsson; Kristin Thorisdottir; Rafn Ragnarsson; Kristrun R Benediktsdottir; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Cristina Corredera; Victoria Fuentelsaz; Pilar Grasa; Sebastian Navarrete; Fernando Fuertes; Maria D García-Prats; Enrique Sanambrosio; Angeles Panadero; Ana De Juan; Almudena Garcia; Fernando Rivera; Dolores Planelles; Virtudes Soriano; Celia Requena; Katja K Aben; Michelle M van Rossum; Ruben G H M Cremers; Inge M van Oort; Dick-Johan van Spronsen; Jack A Schalken; Wilbert H M Peters; Brian T Helfand; Jenny L Donovan; Freddie C Hamdy; Daniel Badescu; Ovidiu Codreanu; Mariana Jinga; Irma E Csiki; Vali Constantinescu; Paula Badea; Ioan N Mates; Daniela E Dinu; Adrian Constantin; Dana Mates; Sjofn Kristjansdottir; Bjarni A Agnarsson; Eirikur Jonsson; Rosa B Barkardottir; Gudmundur V Einarsson; Fridbjorn Sigurdsson; Pall H Moller; Tryggvi Stefansson; Trausti Valdimarsson; Oskar T Johannsson; Helgi Sigurdsson; Thorvaldur Jonsson; Jon G Jonasson; Laufey Tryggvadottir; Terri Rice; Helen M Hansen; Yuanyuan Xiao; Daniel H Lachance; Brian Patrick O Neill; Matthew L Kosel; Paul A Decker; Gudmar Thorleifsson; Hrefna Johannsdottir; Hafdis T Helgadottir; Asgeir Sigurdsson; Valgerdur Steinthorsdottir; Annika Lindblom; Robert S Sandler; Temitope O Keku; Karina Banasik; Torben Jørgensen; Daniel R Witte; Torben Hansen; Oluf Pedersen; Viorel Jinga; David E Neal; William J Catalona; Margaret Wrensch; John Wiencke; Robert B Jenkins; Eduardo Nagore; Ulla Vogel; Lambertus A Kiemeney; Rajiv Kumar; José I Mayordomo; Jon H Olafsson; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson Journal: Nat Genet Date: 2011-09-25 Impact factor: 38.330
Authors: Kathleen M Egan; Reid C Thompson; L B Nabors; Jeffrey J Olson; Daniel J Brat; Renato V Larocca; Steven Brem; Paul L Moots; Melissa H Madden; James E Browning; Y Ann Chen Journal: J Neurooncol Date: 2011-01-04 Impact factor: 4.130
Authors: Tatianna C Larman; Steven R DePalma; Angela G Hadjipanayis; Alexei Protopopov; Jianhua Zhang; Stacey B Gabriel; Lynda Chin; Christine E Seidman; Raju Kucherlapati; J G Seidman Journal: Proc Natl Acad Sci U S A Date: 2012-08-13 Impact factor: 11.205
Authors: Ernest T Lam; Paige M Bracci; Elizabeth A Holly; Catherine Chu; Annie Poon; Eunice Wan; Krystal White; Pui-Yan Kwok; Ludmila Pawlikowska; Gregory J Tranah Journal: Cancer Res Date: 2011-12-15 Impact factor: 12.701
Authors: Anna M Czarnecka; Tomasz Krawczyk; Marek Zdrozny; Jan Lubiński; Rebecca S Arnold; Wojciech Kukwa; Anna Scińska; Paweł Golik; Ewa Bartnik; John A Petros Journal: Breast Cancer Res Treat Date: 2009-03-06 Impact factor: 4.872